Change search
ReferencesLink to record
Permanent link

Direct link
Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells
Umeå University, Faculty of Medicine, Department of Molecular Biology (Faculty of Medicine). (Hallberg)
Greifswald, Germany.
New South Wales, Australia.
Umeå University, Faculty of Medicine, Department of Molecular Biology (Faculty of Medicine). (Hallberg)
Show others and affiliations
2013 (English)In: The FEBS Journal, ISSN 1742-464X, E-ISSN 1742-4658, Vol. 280, no 21, Special Issue, 5269-5282 p.Article in journal (Refereed) Published
Abstract [en]

Activation of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is a key oncogenic mechanism in a growing number of tumor types. In the majority of cases, ALK is activated by fusion with a dimerizing partner protein as a result of chromosomal translocation events, most studied in the case of the nucleophosmin-ALK and echinoderm microtubule-associated protein-like 4-ALK oncoproteins. It is now also appreciated that the full-length ALK receptor can be activated by point mutations and by deletions within the extracellular domain, such as those observed in neuroblastoma. Several studies have employed phosphoproteomics approaches to find substrates of ALK fusion proteins. In this study, we used MS-based phosphotyrosine profiling to characterize phosphotyrosine signaling events associated with the full-length ALK receptor. A number of previously identified and novel targets were identified. One of these, signal transducer and activator of transcription 3 (STAT3), has previously been observed to be activated in response to oncogenic ALK signaling, but the significance of this in signaling from the full-length ALK receptor has not been explored further. We show here that activated ALK robustly activates STAT3 on Tyr705 in a number of independent neuroblastoma cell lines. Furthermore, knockdown of STAT3 by RNA interference resulted in a reduction in myelocytomatosis neuroblastom (MYCN) protein levels downstream of ALK signaling. These observations, together with a decreased level of MYCN and inhibition of neuroblastoma cell growth in the presence of STAT3 inhibitors, suggest that activation of STAT3 is important for ALK signaling activity in neuroblastoma.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2013. Vol. 280, no 21, Special Issue, 5269-5282 p.
Keyword [en]
anaplastic lymphoma kinase, cancer, neuroblastoma, SHP-2, signal transducer and activator of transcription 3 (STAT3)
National Category
Cell and Molecular Biology Cancer and Oncology
URN: urn:nbn:se:umu:diva-81092DOI: 10.1111/febs.12453PubMedID: 23889739OAI: diva2:652983
6th Garvan Signalling Symposium, 2012
Swedish Cancer Society, 12-0722, 120796Swedish Research Council, 621-2011-5181, 521-2012-2831

Special Issue: Frontiers in Cell Signalling, and Ca2+-Signalling and Transport in Health and Disease

Available from: 2013-10-02 Created: 2013-10-02 Last updated: 2015-09-01Bibliographically approved
In thesis
1. Mechanistic Implications and Characterization of Anaplastic Lymphoma Kinase (ALK) mutations in Neuroblastoma
Open this publication in new window or tab >>Mechanistic Implications and Characterization of Anaplastic Lymphoma Kinase (ALK) mutations in Neuroblastoma
2015 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that was first reported as a fusion partner of nucleophosmin in Anaplastic large cell lymphoma in 1994. ALK is involved in myriad of cancers including neuroblastoma which is the most common extracranial solid tumor affecting young children. It arises in the neural crest cells of sympathetic nervous system origin and is responsible for 12% of all childhood cancer deaths. Several point mutations in ALK have been described in both familial and sporadic neuroblastoma.

With the aim to understand the role of ALK in neuroblastoma further, we investigated the point mutations in ALK reported in patients. Using cell culture based methods and Drosophila as a model organism; we first characterized these mutations under three broad categories: 1) Ligand independent mutations that were constitutively active, 2) Kinase dead mutation and 3) Ligand dependent mutations that behaved as inducible wild type. Further, to understand the activation mechanism of ALK, we constructed mutations that could potentially alter ALK’s conformation based on the available crystal structure. From the data generated, we were able to provide a new perspective to the activation of full length ALK receptor. This was more in line with activation mechanism of insulin receptor and different from that suggested for ALK fusion protein. From a clinical point of view, all the mutations in the study were blocked to different degrees using the ALK inhibitor, crizotinib. Lastly, we identified potential downstream targets of ALK using phosphoproteomics. From the various targets identified, we focused on STAT3 and confirmed its role as a mediator in ALK initiated MYCN transcription. We showed that STAT3 inhibition led to reduction of MYCN levels and thereby identifying it as a potential therapeutic target in neuroblastoma. Overall, our study highlights clinical relevance of ALK mutations in neuroblastoma and from a basic biology viewpoint; it reveals important mechanistic insight into receptor activation.

Place, publisher, year, edition, pages
Umeå: Umeå Universitet, 2015. 79 p.
Umeå University medical dissertations, ISSN 0346-6612 ; 1709
neuroblastoma, ALK, crizotinib, receptor tyrosine kinase
National Category
Cell and Molecular Biology
Research subject
Molecular Biology
urn:nbn:se:umu:diva-106663 (URN)978-91-7601-254-3 (ISBN)
Public defence
2015-10-02, KBC-huset, Stora hörsalen, KKB3B1, Umeå universitet, Umeå, 09:00 (English)
Available from: 2015-09-04 Created: 2015-07-28 Last updated: 2015-09-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sattu, KamarajUmapathy, GaneshSchönherr, ChristinaRuuth, KristinaChand, DaminiWitek, BarbaraHugosson, FredrikPalmer, Ruth HHallberg, Bengt
By organisation
Department of Molecular Biology (Faculty of Medicine)Department of Molecular Biology (Faculty of Science and Technology)
In the same journal
The FEBS Journal
Cell and Molecular BiologyCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 184 hits
ReferencesLink to record
Permanent link

Direct link